KYMR compared with MDGL: revenue, margins and what each company keeps, and the suppliers and customers both name

KYMRKymera Therapeutics, Inc.

Mkt capRevenueRevenue

MDGLMadrigal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

KYMRKymera Therapeutics, Inc.

MDGLMadrigal Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only KYMR 4

GILDGilead Sciencescustomer

VERXVertex Pharmaceuticalscustomer

SNYSanoficustomer

SNYNFSanoficustomer

Shared 0

No shared counterparties.

Only MDGL 8

PFEPfizersupplier

—Gregory Pharmaceutical Holdings, Inc. (d/b/a UPM Pharmaceuticals)unlistedsupplier

—Rocheunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Cowen

unlistedsupplier

4 more · MDGL chain ›

KYMRKymera Therapeutics, Inc.

131.91▲+3.45%

Mkt cap$10.8BRevenue$65MQ2 FY26Revenue$39MFY25

MDGLMadrigal Pharmaceuticals, Inc.

463.39▲+7.48%

Regular sessionNov 3 '26

Mkt cap$9.9BRevenue$431MQ3 FY26Revenue$958MFY25

Compare

Regular sessionNov 3 '26

KYMRKymera Therapeutics, Inc.

MDGLMadrigal Pharmaceuticals, Inc.

131.91▲+3.45%

Price

463.39▲+7.48%

$10.8B

Mkt cap

$9.9B

Q2 FY26$65M

Revenue

$431MQ3 FY26

FY25$39M

Revenue

$958MFY25

KYMR131.91▲+3.45%vsMDGL463.39▲+7.48%Regular sessionNov 3 '26